Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR240550 with gemcitabine + carboplatin in metastatic triple-negative breast cancer
2009-016091-80Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iniparib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Nov 2009; status: completed.
02
Drugs
iniparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2009-016091-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016091-80.